CY1126070T1 - Φωσφορικα και φωσφονικα παραγωγα των 7-αμινο-5-θειο-θειαζολο[4,5-d]πυριμιδινων και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων που σχετιζονται με αυξημενα επιπεδα toy cx3cr1 και/ή toy cx3cl1 - Google Patents
Φωσφορικα και φωσφονικα παραγωγα των 7-αμινο-5-θειο-θειαζολο[4,5-d]πυριμιδινων και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων που σχετιζονται με αυξημενα επιπεδα toy cx3cr1 και/ή toy cx3cl1Info
- Publication number
- CY1126070T1 CY1126070T1 CY20231100281T CY231100281T CY1126070T1 CY 1126070 T1 CY1126070 T1 CY 1126070T1 CY 20231100281 T CY20231100281 T CY 20231100281T CY 231100281 T CY231100281 T CY 231100281T CY 1126070 T1 CY1126070 T1 CY 1126070T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diseases
- cx3cl1
- cx3cr1
- increased levels
- thiazolo
- Prior art date
Links
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 title abstract 2
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 title abstract 2
- 102100020997 Fractalkine Human genes 0.000 title abstract 2
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000038016 acute inflammation Diseases 0.000 abstract 1
- 230000006022 acute inflammation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρέχεται μία ένωση του τύπου (Ι), όπου τα R1, R2, Q1 και ο τύπος (Χ) είναι όπως ορίζονται στο παρόν, ενώσεις οι οποίες είναι χρήσιμες στη θεραπευτική αγωγή νόσων και διαταραχών που σχετίζονται με αυξημένα επίπεδα του CX3CR1 και/ή του CX3CL1, συγκεκριμένα της οξείας και/ή της χρόνιας φλεγμονής, οφθαλμικών νόσων, πνευμονικών νόσων, δερματικών νόσων, νόσων των αρθρώσεων και/ή των οστών, αυτοάνοσων νόσων, καρδιαγγειακών νόσων, μεταβολικών νόσων, εγκεφαλικών νόσων, νευροεκφυλιστικών νόσων, πόνου, καρκίνου, ηπατικών νόσων, νεφρικών νόσων, γαστρεντερικών νόσων, ιού ανοσοανεπάρκειας του ανθρώπου και ψυχικών διαταραχών.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811169.0A GB201811169D0 (en) | 2018-07-06 | 2018-07-06 | New compounds |
| PCT/EP2019/068169 WO2020008064A1 (en) | 2018-07-06 | 2019-07-05 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1126070T1 true CY1126070T1 (el) | 2023-11-15 |
Family
ID=63273083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20231100281T CY1126070T1 (el) | 2018-07-06 | 2023-06-15 | Φωσφορικα και φωσφονικα παραγωγα των 7-αμινο-5-θειο-θειαζολο[4,5-d]πυριμιδινων και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων που σχετιζονται με αυξημενα επιπεδα toy cx3cr1 και/ή toy cx3cl1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20210292349A1 (el) |
| EP (1) | EP3818065B1 (el) |
| JP (1) | JP7506653B2 (el) |
| KR (1) | KR20210032403A (el) |
| CN (1) | CN112867725A (el) |
| AU (1) | AU2019297572A1 (el) |
| CA (1) | CA3105566A1 (el) |
| CY (1) | CY1126070T1 (el) |
| DK (1) | DK3818065T3 (el) |
| ES (1) | ES2945561T3 (el) |
| FI (1) | FI3818065T3 (el) |
| GB (1) | GB201811169D0 (el) |
| HR (1) | HRP20230532T1 (el) |
| HU (1) | HUE062011T2 (el) |
| IL (1) | IL279818B2 (el) |
| LT (1) | LT3818065T (el) |
| MX (1) | MX2021000011A (el) |
| PL (1) | PL3818065T3 (el) |
| PT (1) | PT3818065T (el) |
| SG (1) | SG11202100014RA (el) |
| SI (1) | SI3818065T1 (el) |
| WO (1) | WO2020008064A1 (el) |
| ZA (1) | ZA202100192B (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0101082D0 (sv) * | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| BRPI0411122A (pt) * | 2003-06-27 | 2006-07-18 | Pfizer Prod Inc | pirazol[3,4-b]piridin-6-onas como inibidores gsk-3 |
| WO2005033115A1 (en) | 2003-10-07 | 2005-04-14 | Astrazeneca Ab | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
| DE602005011844D1 (de) * | 2004-11-02 | 2009-01-29 | Pfizer | Sulfonylbenzimidazolderivate |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| US8338593B2 (en) | 2006-07-07 | 2012-12-25 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| CN101516893B (zh) * | 2006-09-29 | 2011-11-30 | 阿斯利康(瑞典)有限公司 | 5,7-二取代的[1,3]噻唑并[4,5-d]嘧啶-2(3h)-酮衍生物和它们在治疗中的用途 |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| NZ576519A (en) | 2006-09-29 | 2011-11-25 | Astrazeneca Ab | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5-d] pyrimidin-2 (3h)-amine derivatives and their use in therapy |
| PE20091102A1 (es) * | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
| AR071036A1 (es) * | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
| CN103118682A (zh) * | 2010-04-30 | 2013-05-22 | 加利福尼亚大学校务委员会 | 合成tlr7激动剂的磷脂缀合物的用途 |
| CN104640444B (zh) * | 2012-06-16 | 2016-12-14 | 河南美泰宝生物制药有限公司 | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 |
| US20180222922A1 (en) | 2015-06-08 | 2018-08-09 | The Johns Hopkins University | Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1) |
| GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
-
2018
- 2018-07-06 GB GBGB1811169.0A patent/GB201811169D0/en not_active Ceased
-
2019
- 2019-07-05 LT LTEPPCT/EP2019/068169T patent/LT3818065T/lt unknown
- 2019-07-05 MX MX2021000011A patent/MX2021000011A/es unknown
- 2019-07-05 DK DK19739234.3T patent/DK3818065T3/da active
- 2019-07-05 PT PT197392343T patent/PT3818065T/pt unknown
- 2019-07-05 HR HRP20230532TT patent/HRP20230532T1/hr unknown
- 2019-07-05 EP EP19739234.3A patent/EP3818065B1/en active Active
- 2019-07-05 PL PL19739234.3T patent/PL3818065T3/pl unknown
- 2019-07-05 ES ES19739234T patent/ES2945561T3/es active Active
- 2019-07-05 SG SG11202100014RA patent/SG11202100014RA/en unknown
- 2019-07-05 IL IL279818A patent/IL279818B2/en unknown
- 2019-07-05 CN CN201980057603.6A patent/CN112867725A/zh active Pending
- 2019-07-05 KR KR1020217003104A patent/KR20210032403A/ko not_active Application Discontinuation
- 2019-07-05 CA CA3105566A patent/CA3105566A1/en active Pending
- 2019-07-05 JP JP2021500175A patent/JP7506653B2/ja active Active
- 2019-07-05 FI FIEP19739234.3T patent/FI3818065T3/fi active
- 2019-07-05 US US17/257,917 patent/US20210292349A1/en active Pending
- 2019-07-05 WO PCT/EP2019/068169 patent/WO2020008064A1/en unknown
- 2019-07-05 AU AU2019297572A patent/AU2019297572A1/en active Pending
- 2019-07-05 HU HUE19739234A patent/HUE062011T2/hu unknown
- 2019-07-05 SI SI201930537T patent/SI3818065T1/sl unknown
-
2021
- 2021-01-12 ZA ZA2021/00192A patent/ZA202100192B/en unknown
- 2021-07-09 US US17/372,125 patent/US11339183B2/en active Active
-
2023
- 2023-06-15 CY CY20231100281T patent/CY1126070T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201811169D0 (en) | 2018-08-29 |
| US20210340167A1 (en) | 2021-11-04 |
| MX2021000011A (es) | 2021-05-12 |
| AU2019297572A1 (en) | 2021-01-28 |
| ZA202100192B (en) | 2023-07-26 |
| WO2020008064A1 (en) | 2020-01-09 |
| IL279818B2 (en) | 2024-06-01 |
| SG11202100014RA (en) | 2021-01-28 |
| CN112867725A (zh) | 2021-05-28 |
| LT3818065T (lt) | 2023-06-26 |
| PT3818065T (pt) | 2023-05-30 |
| IL279818B1 (en) | 2024-02-01 |
| ES2945561T3 (es) | 2023-07-04 |
| PL3818065T3 (pl) | 2023-10-09 |
| JP2021530474A (ja) | 2021-11-11 |
| HRP20230532T1 (hr) | 2023-08-04 |
| KR20210032403A (ko) | 2021-03-24 |
| EP3818065A1 (en) | 2021-05-12 |
| EP3818065B1 (en) | 2023-03-15 |
| CA3105566A1 (en) | 2020-01-09 |
| FI3818065T3 (fi) | 2023-06-13 |
| US20210292349A1 (en) | 2021-09-23 |
| DK3818065T3 (da) | 2023-05-15 |
| US11339183B2 (en) | 2022-05-24 |
| HUE062011T2 (hu) | 2023-09-28 |
| JP7506653B2 (ja) | 2024-06-26 |
| SI3818065T1 (sl) | 2023-08-31 |
| IL279818A (en) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1126070T1 (el) | Φωσφορικα και φωσφονικα παραγωγα των 7-αμινο-5-θειο-θειαζολο[4,5-d]πυριμιδινων και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων που σχετιζονται με αυξημενα επιπεδα toy cx3cr1 και/ή toy cx3cl1 | |
| CY1123395T1 (el) | Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων | |
| MX2017016611A (es) | Moduladores de tgr5 y metodos de uso de los mismos. | |
| CY1126080T1 (el) | Χορηγηση αδενο-σχετιζομενου ιικου διαβιβαστη μικρο-δυστροφινης με εξειδικευση στους μυς για τη θεραπευτικη αντιμετωπιση της μυïκης δυστροφιας | |
| CY1124484T1 (el) | 2-ετεροαρυλο-3-οξο-2,3-διυδροπυριδαζινο-4-καρβοξαμιδια για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1121261T1 (el) | Ενωση τριαζινης και χρηση εξ αυτης για ιατρικους σκοπους | |
| CY1117776T1 (el) | Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| DK3906066T3 (da) | Geneterapikonstruktioner til behandling af wilsons sygdom | |
| SG158919A1 (en) | Constructs binding to phosphatidylserine and their use in disease treatment | |
| CY1119790T1 (el) | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας | |
| CY1113136T1 (el) | Αντιμετωπιση των διαταραχων των χονδρων με ton fgf-18 | |
| DK3749308T3 (da) | Behandling af patienter med klassisk fabrys sygdom med migalastat | |
| CY1119371T1 (el) | Υποκατεστημενες ενωσεις καρβοξαμιδιων τετραϋδροκαρβαζολης και καρβαζολης χρησιμες ως αναστολεις κινασων | |
| CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA201791727A1 (ru) | 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии | |
| CY1121930T1 (el) | Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| EA202090564A1 (ru) | Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри | |
| EP3801340A4 (en) | ELECTROTHERMAL THERAPY FOR THE TREATMENT OF DISEASE OR UNWANTED TISSUE | |
| EP3831412A4 (en) | TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE | |
| CY1120642T1 (el) | Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση | |
| CY1122892T1 (el) | Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
| EA202092459A1 (ru) | Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают |